Portal de investigación
Overexpression of genes involved in lymphocyte activation and regulation are associated with reduced CRM-derived cardiac remodelling after STEMI.
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Perez-Sole, Nerea
- Forteza, Maria J
Grupos y Plataformas de I+D+i
Abstract
AIMS: Lymphopenia after ST-segment elevation myocardial infarction (STEMI) correlates with deleterious cardiac consequences and worse prognosis. An in-depth examination of genes implicated in lymphocyte proliferation, activation and regulation and their association with short- and long-term cardiac structure and function is therefore of great interest. METHODS: Peripheral blood mononuclear cells were isolated from 10 control subjects and 64 patients with a first STEMI treated with primary percutaneous coronary intervention and submitted to cardiac magnetic resonance after 1 week and 6 months. mRNA expression of genes implicated in lymphocyte activation (CD25 and CD69) and regulation [programmed death (PD)-1 and cytotoxic T-lymphocyte antigen (CTLA)-4] were determined by qRT-PCR. RESULTS: In comparison to controls, STEMI patients showed heightened mRNA expression of CD25 and lower PD-1 and CTLA-4 96 h after coronary reperfusion. Patients with extensive infarctions (>30% of left ventricular mass) at 1 week displayed a notable reduction in CD25, CD69, PD-1, and CTLA-4 expression (p < 0.05). However, CD25 was the only predictor of 1-week extensive infarct size in multivariate logistic regression analysis (odds ratio 0.019; 95% confidence interval [0.001-0.505]; p = 0.018). Regarding long-term ventricular function, mRNA expression of CD25 under the mean value was associated with worse ventricular function and more adverse remodelling. CONCLUSIONS: Following STEMI, heightened expression of genes expressed in regulatory T cells (CD25 and CD69) and immune checkpoints (PD-1 and CTLA-4) correlates with a better short- and long-term cardiac structure and function. Advancing understanding of the pathophysiology of lymphopenia and evaluating novel immunomodulatory therapies will help translate these results into future clinical trials.
Copyright © 2021 Elsevier B.V. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1567-5769, 1878-1705
- Tipo:
- Article
- Páginas:
- 107490-107490
- PubMed:
- 33677257
INTERNATIONAL IMMUNOPHARMACOLOGY Elsevier BV
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- Lymphocyte; Myocardial infarction; Ventricular remodelling
Financiación
Proyectos y Estudios Clínicos
Estudio multidisciplinar de la obstrucción microvascular y su reparación tras un infarto agudo de miocardio: de la arteria coronaria a la microcirculación. Foco en el factor VEGF-A165b (PI17/01836).
Investigador Principal: VICENT BODÍ PERIS
PI17/01836 . INSTITUTO SALUD CARLOS III . 2018
Un estudio multidisciplinar para avanzar en el entendimiento de los mecanismos básicos y la exploración de nuevas oportunidades terapéuticas en el infarto agudo de miocardio. Foco en los factores VEGF-A165b y ST2.
Investigador Principal: CÉSAR RIOS NAVARRO
FI18/00320 . INSTITUTO SALUD CARLOS III . 2019
Resolution of microvascular obstruction after myocardial infarction. A multidisciplinary approach to assess the structural and clinical consequences and to evaluate new therapeutic options.
Investigador Principal: VICENT BODÍ PERIS
PI20/00637 . INSTITUTO SALUD CARLOS III . 2021
Cita
de Dios E,Rios C,Perez N,Gavara J,Marcos V,Forteza MJ,Oltra R,Vila JM,Chorro FJ,Bodi V. Overexpression of genes involved in lymphocyte activation and regulation are associated with reduced CRM-derived cardiac remodelling after STEMI. Int Immunopharmacol. 2021. 95. p. 107490-107490. IF:5,714. (1).
Overexpression of genes involved in lymphocyte activation and regulation are associated with reduced CRM-derived cardiac remodelling after STEMI. de Dios E, Rios C, Perez N, Gavara J, Marcos V, Forteza MJ, Oltra R et al. INTERNATIONAL IMMUNOPHARMACOLOGY. 2021 junio 01. 95107490-107490. DOI:10.1016/j.intimp.2021.107490. PMID:33677257.
